PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33494360-4 2021 Mouse models of exercise have shown therapeutic efficacy across numerous cancer models, at least in part due to the secretion of adrenaline, which mobilizes cells of the immune system, i.e., cytotoxic T and natural killer (NK) cells, through signaling of the beta-2 adrenergic receptor (beta2AR). Epinephrine 129-139 adrenergic receptor, beta 2 Mus musculus 259-285 1383507-5 1992 That is, when the effects of epinephrine on cellular cAMP levels were measured in LTT or control L-WT beta 2AR cells little desensitization was apparent. Epinephrine 29-40 adrenergic receptor, beta 2 Mus musculus 102-110 1383507-6 1992 Further, cellular cAMP excursions in response to even very high concentrations of epinephrine were very small in control L-WT beta 2AR cells as compared to control S49 WT cells. Epinephrine 82-93 adrenergic receptor, beta 2 Mus musculus 126-134 32483173-4 2020 In wounded skin, keratinocytes produce epinephrine (EPI) that leads to cell motility inhibition by beta2-adrenergic receptor (beta2-AR) activation thus delay wound healing. Epinephrine 39-50 adrenergic receptor, beta 2 Mus musculus 99-124 32483173-4 2020 In wounded skin, keratinocytes produce epinephrine (EPI) that leads to cell motility inhibition by beta2-adrenergic receptor (beta2-AR) activation thus delay wound healing. Epinephrine 52-55 adrenergic receptor, beta 2 Mus musculus 99-124 32045472-3 2020 We demonstrate here a role for the beta2-adrenergic receptor (beta2-AR), which binds the stress mediators adrenaline and noradrenaline, in modulating host response to mouse cytomegalovirus (MCMV) infection. Epinephrine 106-116 adrenergic receptor, beta 2 Mus musculus 35-60 29178678-9 2018 CONCLUSIONS: Blockade of beta2-adrenoceptor can deteriorate systemic anaphylaxis by augmenting hyperpermeability-induced increase in plasma extravasation by inhibiting beneficial effects of epinephrine released from the adrenal glands in anesthetized mice. Epinephrine 190-201 adrenergic receptor, beta 2 Mus musculus 25-43 27541735-11 2016 Furthermore, inhibition of beta2AR dephosphorylation by okadaic acid, a phosphatase 2A inhibitor, impaired the recovery of internalized beta2ARs and reduced the cardiomyocyte contraction rate in response to epinephrine. Epinephrine 207-218 adrenergic receptor, beta 2 Mus musculus 27-34 26612065-5 2016 Agonist and antagonist studies indicated that adrenaline-induced TGF-beta3 mRNA expression is mediated via beta2 -adrenoceptor. Epinephrine 46-56 adrenergic receptor, beta 2 Mus musculus 107-126 26909542-1 2016 Mice lacking the endogenous beta2-adrenoceptor (beta2AR) agonist epinephrine (phenylethanolamine N-methyltransferase [PNMT]-knockout mice) are resistant to developing an "asthma-like" phenotype in an ovalbumin sensitization and challenge (Ova S/C) model, and chronic administration of beta2AR agonists to PNMT-KO mice restores the phenotype. Epinephrine 65-76 adrenergic receptor, beta 2 Mus musculus 28-46 26909542-1 2016 Mice lacking the endogenous beta2-adrenoceptor (beta2AR) agonist epinephrine (phenylethanolamine N-methyltransferase [PNMT]-knockout mice) are resistant to developing an "asthma-like" phenotype in an ovalbumin sensitization and challenge (Ova S/C) model, and chronic administration of beta2AR agonists to PNMT-KO mice restores the phenotype. Epinephrine 65-76 adrenergic receptor, beta 2 Mus musculus 48-55 26909542-1 2016 Mice lacking the endogenous beta2-adrenoceptor (beta2AR) agonist epinephrine (phenylethanolamine N-methyltransferase [PNMT]-knockout mice) are resistant to developing an "asthma-like" phenotype in an ovalbumin sensitization and challenge (Ova S/C) model, and chronic administration of beta2AR agonists to PNMT-KO mice restores the phenotype. Epinephrine 65-76 adrenergic receptor, beta 2 Mus musculus 285-292 26909542-2 2016 Based on these and other studies showing differential effects of various beta2AR ligands on the asthma phenotype, we have speculated that the permissive effect of endogenous epinephrine and exogenous beta2AR agonists on allergic lung inflammation can be explained by qualitative beta2AR signaling. Epinephrine 174-185 adrenergic receptor, beta 2 Mus musculus 73-80 27154061-8 2016 RESULTS: We uncovered that adrenaline promoted DEN-induced hepatocarcinogenesis, which was reversed by the ADRB2 antagonist ICI118,551. Epinephrine 27-37 adrenergic receptor, beta 2 Mus musculus 107-112 25161169-1 2014 It has been suggested that there is a link between epinephrine synthesis and the development of beta2-adrenoceptor-mediated effects, but it remains to be determined whether this development is triggered by epinephrine. Epinephrine 51-62 adrenergic receptor, beta 2 Mus musculus 96-114 26211486-1 2015 BACKGROUND AND PURPOSE: Our previous studies have shown the beta2 -adrenoceptor and its endogenous ligand, adrenaline, are required for development of the asthma phenotype in murine asthma models. Epinephrine 107-117 adrenergic receptor, beta 2 Mus musculus 60-79 25161169-12 2014 In conclusion, epinephrine is crucial for beta2-adrenoceptor-mediated vasodilation and facilitation of norepinephrine release. Epinephrine 15-26 adrenergic receptor, beta 2 Mus musculus 42-60 24374096-3 2014 This adrenaline-induced REDD1 expression was completely blocked by beta2-adrenoceptor selective antagonist ICI 118,551, whereas beta2-adrenoceptor specific agonist salmeterol markedly enhanced REDD1 expression. Epinephrine 5-15 adrenergic receptor, beta 2 Mus musculus 67-85 24886966-12 2014 Prednisolone and epinephrine-induced leukocyte cell death was prevented by GCR and beta2-AR blockade, respectively. Epinephrine 17-28 adrenergic receptor, beta 2 Mus musculus 83-91 24374096-6 2014 Thus, increased intracellular cAMP level resulting from beta2-adrenoceptor stimulation appeared to be responsible for adrenaline-induced REDD1 mRNA expression. Epinephrine 118-128 adrenergic receptor, beta 2 Mus musculus 56-74 24057680-1 2014 PURPOSE: In mouse models of prostate cancer, increased epinephrine levels accelerated tumor growth via the beta2-adrenoreceptor/PKA signaling pathway. Epinephrine 55-66 adrenergic receptor, beta 2 Mus musculus 107-127 24863408-5 2014 While the beta2-adrenoceptor-selective antagonist ICI 118,551 completely blocked adrenaline-induced TG2 mRNA expression, the beta2-adrenoceptor specific agonist salmeterol increased TG2 expression. Epinephrine 81-91 adrenergic receptor, beta 2 Mus musculus 10-28 23204390-2 2013 The first potent beta2AR agonist discovered and widely used in reversing the airway constriction associated with asthma exacerbation was the endogenous activator of the beta2AR, epinephrine. Epinephrine 178-189 adrenergic receptor, beta 2 Mus musculus 17-24 23564017-13 2013 Clenbuterol, and high concentrations of adrenaline and BRL37344 direct the beta2-adrenoceptor partly to Galphai, possibly mediated by beta2-adrenoceptor phosphorylation. Epinephrine 40-50 adrenergic receptor, beta 2 Mus musculus 75-93 23564017-13 2013 Clenbuterol, and high concentrations of adrenaline and BRL37344 direct the beta2-adrenoceptor partly to Galphai, possibly mediated by beta2-adrenoceptor phosphorylation. Epinephrine 40-50 adrenergic receptor, beta 2 Mus musculus 134-152 24121404-5 2014 Further, we demonstrate that beta2-adrenergic receptor-dependent activation of proinflammatory macrophages is critical for epinephrine-mediated IL-6 production. Epinephrine 123-134 adrenergic receptor, beta 2 Mus musculus 29-54 23204390-2 2013 The first potent beta2AR agonist discovered and widely used in reversing the airway constriction associated with asthma exacerbation was the endogenous activator of the beta2AR, epinephrine. Epinephrine 178-189 adrenergic receptor, beta 2 Mus musculus 169-176 23204390-3 2013 In this study, we demonstrate that activation of the beta2AR by epinephrine is paradoxically required for development of the asthma phenotype. Epinephrine 64-75 adrenergic receptor, beta 2 Mus musculus 53-60 10358008-10 1999 beta2-AR -/- mice become hypertensive during exercise and exhibit a greater hypertensive response to epinephrine compared with wild type mice. Epinephrine 101-112 adrenergic receptor, beta 2 Mus musculus 0-8 16051698-6 2005 Isoprenaline, noradrenaline, and adrenaline (-log EC(50) = 5.9, 5.5, and 5.7, respectively) stimulated an association between the beta(2)-adrenoceptor and beta-arrestin 2 at much higher concentrations than required for activation of cAMP accumulation (-log EC(50) = 7.6, 6.3, and 7.7, respectively). Epinephrine 17-27 adrenergic receptor, beta 2 Mus musculus 130-150 7914350-7 1994 Dose-response curves with epinephrine from lean mice were best fit to a two-component model comprised of 23% high affinity (K(act) = 1.42 x 10(-7) M) and 77% low affinity (K(act) = 1.67 x 10(-5) M) components, corresponding to activation of beta 1AR and beta 2AR conjointly, and beta 3AR, respectively. Epinephrine 26-37 adrenergic receptor, beta 2 Mus musculus 254-262 10077231-9 1999 The pA2 value for the specific beta2-adrenoceptor antagonist ICI-118,551 (8.7+/-0.4) as an antagonist of the adrenaline-stimulated cyclic AMP generation were 3 units higher than the value for the betaI-adrenoceptor antagonist atenolol (5.6+/-0.3). Epinephrine 109-119 adrenergic receptor, beta 2 Mus musculus 31-49